Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition) - Valuates Reports

Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition) - Valuates Reports

News Provided by Valuates Reports

PR Newswire

BANGALORE, India, March 11, 2019

BANGALORE, India, March 11, 2019 /PRNewswire/ -- China's fast-track approval time for Overseas Imported New Drugs, is much shorter than any other country, which attracts more and more overseas pharmaceutical manufacturers to enter the Chinese healthcare market. Undoubtedly the Chinese healthcare market of nearly 1.4 billion populations is a huge business opportunities for the overseas pharmaceutical manufacturers.

Valuates_Reports_Logo

This book covers 40 drug varieties that have been approved to market in the United States, EU or Japan but that have not been yet marketed in China, and involves with 33 overseas pharmaceutical manufacturers.

China is one of the fastest growing global economies & has become the world's second largest healthcare market after the United States. Facing a gigantic population and rapid population aging, the Chinese government accelerated the priority approval of innovative drugs and   relaxed the market access for overseas drugs to cope with the clinical urgent demand.

The Chinese "National Medical Products Administration (NMPA)" and the "National Health Commission (NHC)" jointly issued the latest "Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand" on October 23, 2018, which provided a dedicated pathway for priority review and approval of overseas drugs importing to Chinese healthcare market and clarified the specific review and approval procedures.

This book is an essential resource for overseas and multinational pharmaceutical manufacturers to successfully acquire the marketing authorization in China, which provided a detailed guidance for comprehensive knowledge of the latest regulations on review and approval procedures of overseas imported new drugs of Chinese clinical urgent demand to smoothly navigate regulatory requirements step by step.

See the full report : https://reports.valuates.com/sreport/ACCE-Book-32/Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand

Who should buy this report?         

Report Highlights

Total 33 Overseas pharmaceutical manufacturers are covered in this report :

For complete List of Companies Click Here: https://reports.valuates.com/sreport/ACCE-Book-32/Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand

About Us

Our aim is to collate unparalleled Market insights and notify our customers as and when it happens.

Valuates is curating premium Market Research Reports from the leading publishers around the globe. We will help you map your information needs to our report repository of Market research reports and guide you through your purchasing decision.

We are based out of silicon valley of India (Bengaluru) and provide 24/7 online and offline support to all our customers and just a phone call away.

Inquire for sample : https://reports.valuates.com/request/sample/ACCE-Book-32/Guidebook for Review Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand

Inquire for discount: https://reports.valuates.com/request/discount/ACCE-Book-32/Guidebook for Review Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand

Media Contact:
Valuates Reports 
sales@valuates.com
For U.S. Toll Free Call  +1(425)388-2538
For IST Call  +91-8040957137

                                                          

 

 

Voltar noticias em Inglês